SciClone Pharmaceuticals Inc. (SCLN) Sees Strong Trading Volume
SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) shares saw unusually-strong trading volume on Wednesday . Approximately 498,347 shares were traded during mid-day trading, an increase of 20% from the previous session’s volume of 416,329 shares.The stock last traded at $10.33 and had previously closed at $10.57.
The company has a market cap of $515.87 million and a price-to-earnings ratio of 13.94. The stock’s 50 day moving average price is $11.53 and its 200-day moving average price is $11.55.
SciClone Pharmaceuticals (NASDAQ:SCLN) last released its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $0.20 earnings per share (EPS) for the quarter. The firm earned $39 million during the quarter, compared to analysts’ expectations of $37.90 million. On average, analysts expect that SciClone Pharmaceuticals Inc. will post $0.33 EPS for the current year.
In other SciClone Pharmaceuticals news, CFO Wilson Wai-Shun Cheung sold 7,802 shares of the business’s stock in a transaction dated Tuesday, August 16th. The shares were sold at an average price of $10.62, for a total value of $82,857.24. Following the transaction, the chief financial officer now owns 25,000 shares in the company, valued at $265,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
A hedge fund recently raised its stake in SciClone Pharmaceuticals stock. Cornerstone Capital Management Holdings LLC. boosted its position in shares of SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) by 32.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 198,570 shares of the specialty pharmaceutical company’s stock after buying an additional 48,470 shares during the period. Cornerstone Capital Management Holdings LLC. owned about 0.40% of SciClone Pharmaceuticals worth $1,827,000 as of its most recent SEC filing.
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.